Cencora Inc（COR）财务数据CORCencora Inc

Cencora, Inc. (COR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is U.S. Healthcare Solutions, accounting for 88.3% of total sales, equivalent to $74.86B. Other significant revenue streams include Alliance Healthcare and Animal Health. Understanding this composition is critical for investors evaluating how COR navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Cencora, Inc. maintains a gross margin of 3.95%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 1.43%, while the net margin is 0.92%. These profitability ratios, combined with a Return on Equity (ROE) of 104.34%, provide a clear picture of how effectively COR converts its operational activities into shareholder value.

In the context of the broader market, COR competes directly with industry leaders such as CAH and MCK. With a market capitalization of $59.89B, it holds a significant position in the sector. When comparing efficiency, COR's gross margin of 3.95% stands against CAH's 3.87% and MCK's 3.50%. Such benchmarking helps identify whether Cencora, Inc. is trading at a premium or discount relative to its financial performance.

Cencora has shown strong revenue growth, with Q2 2026 revenue at $78.4 billion, up 3.8% year-over-year, and an adjusted EPS increase of 7.5% to $4.75. The gross margin for Q2 2026 was 4.26%, indicating improving profitability.